The device history record for the manufacturing lot was reviewed and the device met all release criteria and there were no discrepancies or unusual findings that relate to the reported event.The explanted corneal inlay has not been returned to the manufacturer at this time.Corneal swelling, inlay shifts in position, inlay removal, and decreased visual acuity are listed in the device labeling as potential risks.(b)(4).Date emdr submitted to fda: 03/03/2017.Reference mdr# 3005956347-2017-00013 for the event involving the initial inlay.
|
A replacement raindrop corneal inlay was implanted in the patient's left eye on (b)(6) 2017.Reference mdr# 3005956347-2017-00013, which was filed for an adverse event involving the first inlay implanted in this patient.Additional information was received and it was learned that one day following inlay exchange, there was significant corneal flap edema and bcdva had worsened to 20/80.On (b)(6) 2017, the replacement inlay was fully decentered and the patient's bcdva was 20/40.The inlay was explanted on (b)(6) 2017.One week post explantation, bcdva improved to 20/30+.On (b)(6) 2017, the patient's bcdva returned to baseline.The inlay decentration was thought to be caused by patient's anatomy.
|